Hasbro, Inc. vs TransMedics Group Inc — how do they compare? Hasbro, Inc. trades at $87.45 (market cap $11.53B), while TransMedics Group Inc trades at $74.92 (market cap $2.54B). The key difference: Hasbro, Inc. is far larger — about 4.5× TransMedics Group Inc's market cap, and Hasbro, Inc. pays a 3.44% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| HAS | TMDX | |
|---|---|---|
Market Cap | $11.53B | $2.54B |
Sector | Consumer Cyclical | Technology |
52-Week High | $105.88 | $150.42 |
52-Week Low | $70.95 | $61.99 |
Enterprise Value | $13.80B | $2.94B |
Dividend Yield | 3.44% | — |
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $81.56, showing minimal daily movement with a 0.01% gain. The stock exhibits a bearish technical signal, with RSI indicating overbought conditions near-term. Fundamentally, the company reported a net loss of -$322.4M in 2025 despite revenue growth to $4.7B, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights upcoming Q2 2026 earnings and new product launches like Blooms by Play-Doh targeting adult consumers.
The outlook remains mixed with analyst consensus leaning bullish (51.5% buy ratings) and a $104.75 price target suggesting 28% upside. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the toy industry. Earnings performance on July 21 will be critical for near-term direction.
TransMedics (TMDX) trades at $73.47, down 0.69% with neutral technical signals. The stock shows strong profitability with 27% net margins and 45% ROE, though Q1 2026 earnings missed expectations. Recent strategic investment in European aviation logistics aims to expand the Organ Care System platform. Analyst consensus remains bullish with a $108.71 price target representing 48% upside potential.
Long-term growth prospects appear solid given TMDX's expanding transplant ecosystem, but near-term margin pressure from expansion investments and execution risks warrant caution. The company maintains competitive advantages in organ transplant logistics, though increased spending and competitive threats from alternatives like Strata Critical Medical present headwinds for shareholder returns.
Trailing returns across standard periods
Latest headlines on both assets
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →